CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for CV Therapeutics, Inc. is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

CV Therapeutics, Inc.
3172 Porter Drive
Phone: (650) 384-8500p:650 384-8500 Palo Alto, CA  94304  United States Ticker: CVTX CVTX
This company was Merged or Acquired on 4/17/2009.
This company ceased filing statements with the SEC on 4/17/2009.
This company is no longer actively traded on any major stock exchange.
This is a Subsidiary, click here for the Parent Company
Business Summary
CV Therapeutics, Inc. is a biopharmaceutical company. The Company is focused primarily on the discovery, development and commercialization of new small molecule drugs for the treatment of cardiovascular diseases. It applies advances in molecular biology and genetics to identify mechanisms of cardiovascular diseases and targets for drug discovery. The Company promotes Ranexa (ranolazine extended-release tablets), focused on primary care physicians in the northeastern United States. Ranexa is used as add-on therapy for the symptomatic treatment of patients with stable angina pectoris who are inadequately controlled or intolerant to first-line antianginal therapies. In April 2009, Gilead Sciences, Inc. announced the completion of its acquisition of the Company.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
-Yes-----

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
12/31/200812/31/2008YesYes---

Industries
SIC Code Description
8731 Commercial physical and biological research
2834 Pharmaceutical preparations

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Chairman of the Board, Chief Executive Officer, Chief Scientific Officer Louis G.Lange 60 8/1/1992 1/1/1992
Chief Financial Officer, Senior Vice President Daniel K.Spiegelman 50 9/1/1999 1/1/1998
Senior Vice President, General Counsel, Secretary Tricia B.Suvari 48 2/1/2007 5/1/2000
7 additional Officers and Directors records available in full report.

General Information
Number of Employees: 550 (As of 12/31/2008)
Outstanding Shares: 64,234,229 (As of 2/19/2009)
Shareholders: 64
Stock Exchange: NASD
Federal Tax Id: 431570294
Fax Number: (650) 858-0390


Copyright © 2023 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Friday, July 21, 2023